Igor Braga Farias

Dr. Igor Braga Farias


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
PSPaulo de Lima Serrano
Paulo de Lima Serrano
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Roberta Ismael Lacerda MachadoRoberta Ismael Lacerda Machado
Roberta Ismael Lacerda Machado
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Juvenile Amyotrophic Lateral Sclerosis is a genetically heterogeneous neurodegenerative disorder, which is frequently misdiagnosed due to low clinical suspicion and little knowledge about disease characteristics. More than 20 different genetic loci have been associated with both sporadic and familial juvenile Amyotrophic Lateral Sclerosis. Currently, almost 40% of cases have an identifiable monogenic basis; type 6, associated with FUS gene variants, is the most prevalent globally. Despite several upper motor neuron-dominant forms being generally associated with long-standing motor symptoms and slowly progressive course, certain subtypes with lower motor neuron-dominant features and early bulbar compromise lead to rapidly progressive motor handicap. For some monogenic forms, there is a well-established genotypic-phenotypic correlation. There are no specific biochemical and neuroimaging biomarkers for the diagnosis of juvenile Amyotrophic Lateral Sclerosis. There are several inherited neurodegenerative and neurometabolic disorders which can lead to the signs of motor neuron impairment. This review emphasizes the importance of high clinical suspicion, assessment, and proper diagnostic work-up for juvenile Amyotrophic Lateral Sclerosis.

Verified
Journal Article
Open access
PDF file
PSPaulo de Lima Serrano
Paulo de Lima Serrano
TRThaiane de Paulo Varollo Rodrigues
Thaiane de Paulo Varollo Rodrigues
LPLeslyê Donato Pinto
Leslyê Donato Pinto
IPIndiara Correia Pereira
Indiara Correia Pereira
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Leukodystrophies represent a large and complex group of inherited disorders affecting the white matter of the central nervous system. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare leukodystrophy which still needs the proper identification of diagnostic, prognostic, and monitoring biomarkers. The aim of this study was to determine the diagnostic and prognostic value of chitinases and neurofilament light chain as biomarkers for ALSP. A cross-sectional study was performed to analyze cerebrospinal fluid levels of chitinases (chitotriosidase and chitinase 3-like 2) and neurofilament light chain in five different groups: (i) normal health individuals; (ii) patients with definitive diagnosis of ALSP and genetic confirmation; (iii) asymptomatic patients with CSF1R variants; (iv) patients with other adult-onset leukodystrophies; and (v) patients with amyotrophic lateral sclerosis (external control group). Chitinase levels showed a statistical correlation with clinical assessment parameters in ALSP patients. Chitinase levels were also distinct between ALSP and the other leukodystrophies. Significant differences were noted in the levels of chitinases and neurofilament light chain comparing symptomatic (ALSP) and asymptomatic individuals with CSF1R variants. This study is the first to establish chitinases as a potential biomarker for ALSP and confirms neurofilament light chain as a good biomarker for primary microgliopathies.

5 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
PSPaulo de Lima Serrano
Paulo de Lima Serrano
JBJoão Paulo Barile
João Paulo Barile
DSDaniel Seneor
Daniel Seneor
PMPatrícia Marques Mendes
Patrícia Marques Mendes
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Background: Acute hepatic porphyrias (AHPs) represent inherited metabolic disorders of the heme biosynthesis pathway, leading to neurological and systemic impairment. Despite the presence of well-recognized chronic symptoms and signs, acute neurological, both neuromuscular and central neurological complications pose a significant challenge in clinical practice, with a potential risk of greater severity and mortality during acute decompensation episodes of AHPs. Care related to the prescription of medications, considering the risk of porphyrinogenicity, is a major and recurring concern in the acute and chronic management of AHP patients. Infectious clinical complications are significant issues in both outpatient and hospital settings for patients with AHPs. It is crucial to identify therapeutic regimens with the best safety and efficacy profiles for treating such infectious complications in AHP patients. The scarcity of structured knowledge available in guidelines and recommendations often leads to the use of therapeutic options with higher potential risks in treating patients with AHPs. Objectives: This review article aims to provide practical recommendations for managing the most significant infectious complications in clinical practice, with a focus on their impact on the clinical care of patients with AHPs.

27 May 2019 in Revue Neurologique
Verified
Journal Article
Closed access
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
LSL.H.L. Silva
L.H.L. Silva
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira

6 February 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PSPaulo de Lima Serrano
Paulo de Lima Serrano
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
JBJoão Paulo Barile
João Paulo Barile
PMPatrícia Marques Mendes
Patrícia Marques Mendes
RCRenan Brandão Rambaldi Cavalheiro
Renan Brandão Rambaldi Cavalheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Secondary hypertension and resistant hypertension may result from potentially treatable acquired or hereditary diseases. Inherited Metabolic Disorders are not routinely included in the differential diagnosis of these contexts associated with hypertension, despite the key importance of diagnosis for several of them which enable the early treatment of them. We aim to discuss the current evidence that indicates that a significant portion of cases of unknown resistant hypertension or suspected secondary hypertension may result from unrecognized Acute Hepatic Porphyria (AHP). Diagnostic work-up for AHP is not routinely performed during the evaluation of patients with resistant or refractory hypertension nor in the investigation of secondary hypertension. AHP may present both with neurological and systemic involvement, and hypertension may be observed as part of acute dysautonomia during acute neurovisceral attacks and as a chronic complication during disease course. As AHP represent a potentially treatable group of metabolic disorders, clinicians should consider the inclusion of this group in the diagnostic evaluation of patients with secondary or resistant hypertension.

12 September 2019 in Revue Neurologique
Verified
Journal Article
Closed access
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
LSL.H.L. Silva
L.H.L. Silva
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira